Nexstim Oyj: German University Hospital Orders Nexstim NBS System with NexSpeech
German University Hospital Orders Nexstim NBS System with NexSpeech
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that a University Hospital in Germany has ordered a Nexstim NBS System with NexSpeech.
The hospital is a new customer for Nexstim. The NBS System with NexSpeech will be used for neuroscientific research and diagnostics.
Nexstim NBS System uses the unique SmartFocus navigated transcranial magnetic stimulation (nTMS) technology which enables accurate and precise stimulation of the brain. SmartFocus nTMS mapping conducted with NBS system is a non-invasive and accessible way of diagnosing the tumour s or other lesion s location. In addition to motor mapping, NBS System can be used also for locating language eloquent areas when used together with NexSpeech module.
Nexstim Oyj: Nexstim Plc Announces Resolutions of the Shareholder s Nomination Board
Nexstim Plc Announces Resolutions of the Shareholder s Nomination Board
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces resolutions of its Shareholder s Nomination Board.
Rohan Hoare, who has been a member of Nexstim s Board of Directors since 2016, and Tomas Holmberg, who has been a member of Nexstim s Board of Directors since 2017, have announced that they will no longer be available to the company s Board of Directors for the period 2021-2022. At its meeting, the Nomination Board of the Company has decided to propose to the General Meeting Timo Hildén and Tero Weckroth as new members of the Board.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Press release, Helsinki, 13 January 2021 at 13.00 New Study Presents Impressive Results of Nexstim SmartFocus® nTMS Language Mapping Nexstim Plc announces that a new study published in. | January 14, 2021
Nexstim Oyj: New Study Presents Impressive Results of Nexstim SmartFocus nTMS Language Mapping
New Study Presents Impressive Results of Nexstim SmartFocus nTMS Language Mapping
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that a new study published in
Cancers in January presents impressive results of nTMS language mapping in a large amount of patients. Using the robustness of Nexstim SmartFocus nTMS data, the authors also introduce a new and more precise classification of what it means to be a language eloquent tumour, challenging the traditional methods that seek to only identify hemispheric dominance for language.
The study Non-Invasive Mapping for Effective Preoperative Guidance to Approach Highly Language-Eloquent Gliomas-A Large Scale Comparative Cohort Study Using a New Classification for Language Eloquence , using Nexstim s NBS System with SmartFocus nTMS, was published by a neurosurgical team at Technical University of Munich (TUM) in Germany.